"This project is an excellent opportunity to develop the compartmentalisation of reactions in emulsion droplets for an entirely new field of application: HTS for drug discovery," said Andrew Griffiths, head of the Chemical Biology Laboratory at ISIS.
"The dScreen Consortium is a great illustration of the 'Pole de Competitivite' policy in France: the development of breakthrough innovations in drug screening through collaborative R&D programs results in strengthening local actors such as the sanofi-aventis research site and in the creation of a U.S. subsidiary company in Alsace. Furthermore, the establishment of a drug screening services platform based on the results of the program will reinforce the capabilities of our cluster," said Pascal Neuville, President of ALSACE BIOVALLEY.
More about dScreen
The aim is to develop a digital microfluidic system for quantitative HTS of bio-active compounds using purified targets and cell-based assays. The very high-throughput will enable the measurement of dose-response curves for every compound in a chemical library. The second objective is to develop a new system for compound storage in which each compound will be stored in droplets using a microfluidic device.
About the ALSACE BIOVALLEY(TM) cluster
The ALSACE BIOVALLEY(TM) cluster's mission is to bring together and support the development and growth of all public and private players involved in the sector of life sciences and healthcare in Alsace. The ALSACE BIOVALLEY(TM) cluster brings together the main organizations supporting the field of life science in Alsace, thus granting all its players a simplified, more efficient and rationalized access to the entire pool of regional resources and skills.
|SOURCE RainDance Technologies|
Copyright©2008 PR Newswire.
All rights reserved